Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results

被引：0
|
作者：
Seneviratne, Lasika C.
Harnden, Kathleen Kiernan
Blau, Sibel
Danso, Michael A.
Berz, David
Guaqueta, Delia Constanza
Schwerkoske, John F.
O'Shaughnessy, Joyce
Patt, Debra A.
Bardia, Aditya
McCann, Kelly Elizabeth
Beelen, Andrew Paul
Zhang, Jingshan
Yi, John S.
Hurvitz, Sara A.
Mardones, Mabel Alejandra
机构：
[1] Los Angeles Canc Network, Los Angeles, CA USA
[2] Inova Schar Canc Inst, Fairfax, VA USA
[3] Northwest Med Specialties, Puyallup, WA USA
[4] Virginia Oncol Associates, Norfolk, VA USA
[5] Virginia Oncol Associates, Virginia Beach, VA USA
[6] Valkyrie Clin Trials Inc, Los Angeles, CA USA
[7] Mem Reg Hosp, Hollywood, FL USA
[8] Minnesota Oncol Hematol PA, Woodbury, MN USA
[9] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[10] Texas Oncol, US Oncol Network, Austin, TX USA
[11] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[12] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[13] Beverly Hills Canc Care, Los Angeles, CA USA
[14] G1 Therapeut Inc, Res Triangle Pk, NC USA
[15] Univ Washington Sch Med, Seattle, WA USA
[16] Fred Hutchinson Canc Ctr, Seattle, WA USA
[17] Rocky Mt Canc Ctr, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1091
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1-metastatic triple-negative breast cancer (mTNBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Yam, Clinton
    Daniel, Brooke R.
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
    Maltoni, Roberta
    Bravaccini, Sara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
  • [33] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Cheng, Shao-Xian
    Chen, Qiu-Chi
    Lin, Guo-He
    Han, Yan-Hong
    Wang, Bi-Cheng
    Dai, Yi
    Zhao, Yan-Xia
    MEDICINE, 2023, 102 (30) : E34486
  • [34] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [35] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study
    Weide, Rudolf
    Bardia, Aditya
    Tolaney, Sara
    Loirat, Delphine
    Punie, Kevin
    Oliveira, Mafalda
    Rugo, Hope
    Brufsky, Adam
    Kalinsky, Kevin
    Cortes, Javier
    O'shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa
    Gianni, Luca
    Piccart-Gebhart, Martine
    Loibl, Sibylle
    Zhu, Yanni
    Phan, See-Chun
    Hurvitz, Sara
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 37 - 37
  • [36] Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    O'Shaughnessy, Joyce
    Punie, Kevin
    Oliveira, Mafalda
    Lynce, Filipa
    Tolaney, Sara M.
    Dalenc, Florence
    Sharma, Priyanka
    Tsai, Michaela L.
    Bardia, Aditya
    Cortes, Javier
    Danso, Michael A.
    Henry, Stephanie
    Perez, Alejandra T.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    Hong, Quan
    Sebastian Olivo, Martin
    Itri, Loretta
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases
    De Moura, Alexandre
    Loirat, Delphine
    Vaillant, Sarah
    Korbi, Sinen
    Kiavue, Nicolas
    Roufai, Diana Bello
    Escalup, Laurence
    Desmaris, Romain
    Vaflard, Pauline
    Cottu, Paul
    Pierga, Jean-Yves
    Bidard, Francois-Clement
    Cabel, Luc
    Acramel, Alexandre
    BREAST CANCER, 2024, 31 (04) : 572 - 580
  • [38] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Spring, Laura M.
    Nakajima, Erika
    Hutchinson, Jennifer
    Viscosi, Elene
    Blouin, Gayle
    Weekes, Colin
    Rugo, Hope
    Moy, Beverly
    Bardia, Aditya
    ONCOLOGIST, 2021, 26 (10): : 827 - 834
  • [39] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
  • [40] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
12345